{'52WeekChange': -0.5226867,
 'SandP52WeekChange': None,
 'address1': '430 East 29th Street',
 'address2': '14th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.46,
 'askSize': 1100,
 'averageDailyVolume10Day': 221062,
 'averageVolume': 121423,
 'averageVolume10days': 221062,
 'beta': 1.515746,
 'beta3Year': None,
 'bid': 12,
 'bidSize': 800,
 'bookValue': 5.023,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.57,
 'dayLow': 12.9,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.171,
 'enterpriseToRevenue': 18.717,
 'enterpriseValue': 312876320,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 13.350286,
 'fiftyTwoWeekHigh': 28.88,
 'fiftyTwoWeekLow': 8.82,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14993911,
 'forwardEps': -2.46,
 'forwardPE': -5.463414,
 'fromCurrency': None,
 'fullTimeEmployees': 172,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.33791,
 'heldPercentInstitutions': 0.47172,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/meiragtx.com',
 'longBusinessSummary': 'MeiraGTx Holdings plc, a clinical-stage gene therapy '
                        'company, focusing on developing treatments for '
                        'patients living with serious diseases. The company '
                        'develops various therapies for ocular diseases, '
                        'including rare inherited blindness, as well as '
                        'Xerostomia following radiation treatment for head and '
                        'neck cancers; neurodegenerative diseases, such as '
                        "amyothrophic lateral sclerosis; and Parkinson's "
                        'diseases. Its programs in clinical development '
                        'include Phase 1/2 clinical stage programs in '
                        'Achromatopsia, X-Linked Retinitis Pigmentosa, '
                        'RPE65-deficiency, and radiation-induced Xerostomia, '
                        "as well as Parkinson's program. The company also "
                        'focuses on initiating a clinical program in '
                        "xerostomia related to Sjogren's syndrome and have "
                        'preclinical programs in neurodegenerative diseases. '
                        'It has a research collaboration agreement with '
                        'Janssen Pharmaceuticals, Inc. to develop regulatable '
                        "gene therapy treatment using the company's "
                        'proprietary riboswitch technology. The company was '
                        'founded in 2015 and is based in New York, New York.',
 'longName': 'MeiraGTx Holdings plc',
 'market': 'us_market',
 'marketCap': 502150656,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_404780252',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -52445512,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.57,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -2.8,
 'phone': '646 860 7985',
 'previousClose': 13.36,
 'priceHint': 2,
 'priceToBook': 2.6756918,
 'priceToSalesTrailing12Months': 30.039093,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.57,
 'regularMarketDayLow': 12.9,
 'regularMarketOpen': 13.57,
 'regularMarketPreviousClose': 13.36,
 'regularMarketPrice': 13.57,
 'regularMarketVolume': 124889,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 37362400,
 'sharesPercentSharesOut': 0.0182,
 'sharesShort': 679788,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 635668,
 'shortName': 'MeiraGTx Holdings plc',
 'shortPercentOfFloat': 0.026600001,
 'shortRatio': 5.24,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'MGTX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.493,
 'twoHundredDayAverage': 15.00036,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '934d1a61-2bc1-31ce-acc9-153361189a8b',
 'volume': 124889,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.meiragtx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10016'}